Heterocyclic Compounds

Matches 101 - 150 out of 12,018	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >

Document	Document Title
WO/2024/011294A1	ANTI-GIARDIAL COMPOUNDS The present disclosure relates to compounds that find application as therapeutics. In particular, the disclosure relates to compounds of Formula (I) or Formula (II) and their pharmaceutically acceptable salt, solvates, or stereoisomers t...
WO/2024/015409A1	CHROMAN DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS Described herein are compounds of Formula (I) and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as estrogen receptor degraders).
WO/2024/015408A1	INDAZOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS Described herein are compounds of Formula I and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as estrogen receptor degraders).
WO/2024/015412A1	TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS Described herein are compounds of Formula I and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as estrogen receptor degraders).
WO/2024/008113A1	FORMAMIDE-SUBSTITUTED HETEROTRICYCLIC DERIVATIVE, METHOD FOR PREPARING SAME, AND USE THEREOF The present invention relates to a formamide-substituted heterotricyclic derivative represented by formula (I), a method for preparing same, and use thereof. The present invention further relates to a pharmaceutical composition comprisin...
WO/2024/008610A1	MACROCYCLIC INHIBITORS OF KRAS FOR THE TREATMENT OF CANCER The present invention relates to compounds of formula (I), wherein R1 to R7, A1 and A2 are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
WO/2024/010336A1	NOVEL COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING SAME The present invention provides a novel compound and an organic light-emitting device using same.
WO/2024/011155A1	OXAZOLE TRPML1 AGONISTS AND USES THEREOF Described herein are oxazole TRPML1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of TRPML1-mediated disorders or diseases.
WO/2024/007997A1	CRYSTAL FORM OF PYRIDONE POLYCYCLIC DERIVATIVE AND PREPARATION METHOD THEREFOR Disclosed in the present invention are a crystal form of a pyridone polycyclic derivative and a preparation method therefor, and particularly a crystal form of a compound as represented by formula (I) and a preparation method therefor.
WO/2024/006916A1	AZETIDINYL PYRIMIDINES AND USES THEREOF AS JAK INHIBITORS Provided herein are compounds useful as inhibitors of Janus kinase (JAK) proteins and in treating JAK-related diseases.
WO/2023/205504A9	FORMULATIONS AND METHODS FOR TREATING EPIDERMOLYSIS BULLOSA SIMPLEX AND RELATED CONDITIONS The invention provides the use of kinase inhibitors and derivatives of staurosporine, such as PKC412, to treat patients having epidermis bullosa simplex (BBS), epidermolytic hyperkeratosis, epidermolytic palmoplantar keratoderma, palmopl...
WO/2024/006879A1	USP1 INHIBITORS AND USES THEREOF Provided herein are inhibitors of ubiquitin-specific-processing Protease 1 (USP1), their pharmaceutical compositions, and methods of use for treating diseases or disorders, such as cancers described herein.
WO/2024/006881A1	WEE1 DEGRADING COMPOUNDS AND USES THEREOF Provided herein are compounds and compositions thereof that reduce WEE1 kinase protein levels. In some embodiments, the compounds and compositions are provided for treatment WEE1 associated diseases such as cancer.
WO/2024/006781A1	ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF The application relates to bifunctional compounds of the general formula I-3' which act as degraders of the estrogen receptor alpha(ERα) and are useful for treating disorders associated with ERα-mediated transcription regulation such a...
WO/2024/002373A1	SUBSTITUTED PYRIMIDINE-FUSED RING INHIBITOR, METHOD FOR PREPARING SAME, AND USE THEREOF The present invention relates to a substituted pyrimidine-fused ring inhibitor, a method for preparing same, and use thereof. Specifically, the compound of the present invention has a structure represented by formula (I). Further disclos...
WO/2023/247666A1	FLUORESCENT PROBES FOR MAGL The invention provides compounds having the general formula (I) wherein A, L, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
WO/2023/247670A1	NEW HETEROCYCLIC-CARBONYL-CYCLIC COMPOUNDS AS MAGL INHIBITORS The present invention provides compounds of formula (I) CB (I) or pharmaceutically acceptable salts thereof, wherein R3 to R5, R4a, B and C are as described herein, compositions including the compounds, processes of manufacturing the com...
WO/2023/245611A1	SMALL MOLECULE COMPOUND WITH TTK INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND USE THEREOF The present invention belongs to the field of organic synthesis medicines, and particularly relates to a small molecule compound with TTK inhibitory activity. The general formula of the small molecule compound is shown in formula (I). Th...
WO/2023/247590A1	TRIAZOLOPYRIDINE AND BENZOISOXAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS The disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprising compounds of formula (I), as well as methods of their use and preparation, are also described.
WO/2023/248240A1	POLYMORPHIC FORMS OF BICTEGRAVIR SODIUM The present disclosure relates to novel crystalline forms of bictegravir sodium and processes for their preparation.
WO/2023/033740A9	COMPOUNDS USEFUL IN MODULATION OF AHR SIGNALLING Compounds of the general formula (I) as described and defined herein, methods for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds and pharmaceutical compositi...
WO/2023/248117A2	TEMPERATURE INTEGRITY SENSOR The present invention relates to a temperature integrity sensor or more precisely a temperature continuity sensor of a product which needs to be kept at a temperature below its degradation temperature, such as for instance a refrigerated...
WO/2023/246777A1	K-RAS MUTANT PROTEIN INHIBITORS The invention relates to KRAS mutant protein inhibitors of formula (I) or formula (II), a composition containing the same and the use thereof.
WO/2023/243686A1	DIHYDROOXADIAZINONE COMPOUND AND PHARMACEUTICAL USE THEREOF The present invention provides a compound that exhibits a PLD-inhibitory activity.　The present invention provides a compound having the following structural formula or the like, or a pharmaceutically acceptable salt thereof. (Each symb...
WO/2023/241137A1	NITROGEN-CONTAINING COMPOUND, ORGANIC ELECTROLUMINESCENT APPARATUS, AND ELECTRONIC DEVICE The present application relates to the technical field of organic electroluminescent materials, and provides a nitrogen-containing compound, and an organic electroluminescent apparatus and an electronic device comprising same. The nitrog...
WO/2023/241136A1	HETEROCYCLIC COMPOUND, ORGANIC ELECTROLUMINESCENT APPARATUS, AND ELECTRONIC DEVICE The present application relates to the technical field of organic electroluminescent materials, and provides a heterocyclic compound, and an organic electroluminescent apparatus and an electronic device comprising same. The heterocyclic ...
WO/2023/240038A1	TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS This disclosure provides compounds of Formula (I) (e.g., Formula (I-aa) (e.g., Formula (I-aa-1), (I-aa-2), (I-aa-3), (I-aa-4), (I-aa-5), or (I-aa-6)), Formula (I-a) (e.g., Formula (I-a-1), (I-a-2), (I-a-3), (I-a-4), (I-a-5), or (I-a-6)),...
WO/2023/237580A1	TRICYCLIC SPIROLACTAM COMPOUNDS WITH ANTIMYCOBACTERIAL ACTIVITY The present invention concerns new tricyclic spirolactams (TriSLas) compounds and their use as a drug, in particular for the prevention and/or treatment of a mycobacterial infection or for the treatment of a disease caused by infection w...
WO/2023/238065A1	NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS Small molecule inhibitors of Nav1.8 voltage-gated sodium ion channel, including compounds of formula (I), (II), (III), (IV), and (V) are described. Also described are pharmaceutical compositions containing a compound of formula (I), (II)...
WO/2023/240263A1	MACROCYCLIC RAS INHIBITORS The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
WO/2023/232946A1	Organic electroluminescent device comprising a compound of Formula (I) and an organic electronic device comprising the organic electroluminescent device The present invention relates to an organic electroluminescent device comprising a compound of Formula (I), and an organic electronic device comprising the organic electroluminescent device.
WO/2023/232145A1	SMALL MOLECULE OF HOMOCAMPTOTHECINS AND USE THEREOF Disclosed in the present invention are a small molecule of homocamptothecins and the use thereof. Specifically disclosed in the present invention are a small molecule of homocamptothecins as shown in formula (I) or a pharmaceutically acc...
WO/2023/231777A1	COMPOUNDS AS BCL-2 INHIBITORS Provided are certain BCL-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
WO/2023/232966A1	MACROCYCLIC OREXIN RECEPTOR AGONISTS AND USES THEREOF Provided herein are compounds of Formula (I), (I), or pharmaceutically acceptable salt thereof, wherein m, n, p, A1, A2, A3, A4, L, R1, R2, R3, R4, Formula (II), (II), V, X, Y and Z are defined herein. Also provided herein are pharmaceut...
WO/2023/232776A1	HALOINDOLE MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER The present invention relates to compounds of formula (I), wherein R1 to R7, A1 and A2 are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
WO/2023/226940A1	USE AND PHARMACEUTICAL COMPOSITION OF INDOLO HEPTAMYL OXIME ANALOG The present application relates to the technical field of medicine, and relates to a use and a pharmaceutical composition of an indolo heptamyl oxime analog, and in particular to a use of a compound of formula (I), and a pharmaceutical c...
WO/2023/229430A1	HETEROARYL DERIVATIVE COMPOUND AND USES THEREOF The present invention relates to a heteroaryl derivative and uses thereof. The heteroaryl derivative of the present invention exhibits excellent inhibitory activity against EGFR, and thus can be effectively used as a therapeutic agent fo...
WO/2023/225041A1	RIPK1 INHIBITORS AND METHODS OF USE Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related disea...
WO/2023/223057A1	MACROCYCLIC COMPOUNDS AND USES THEREOF The invention relates to selected macrocyclic compounds, and their use in the treatment or prevention of diseases and disorders. In particular, though not exclusively, the invention relates to the use of selected macrocyclic compounds in...
WO/2023/222762A1	N6-ADENOSINE-METHYLTRANSFERASE PROTACS AND METHODS OF USE THEREOF The present disclosure relates to proteolysis targeting chimeras (PROTACs) that modulate N6-adenosine-methyltransferase and methods of using the same.
WO/2023/225097A1	PYRIMIDOPYRIMIDONE COMPOUNDS AND METHODS OF USE THEREOF Provided are, inter alia, compounds having a structure of Formula (I)-(VL), pharmaceutical compositions including the same, and methods of use. In one aspect, compounds are provided that can inhibit salt-inducible kinases (SIK) and metho...
WO/2023/225302A1	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF Provided herein are aza-tetracyclic oxazepinyl compounds useful in the treatment of cancers.
WO/2023/224981A1	HSD17B13 INHIBITORS AND USES THEREOF Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such...
WO/2023/222005A1	AROMATIC HETEROCYCLIC COMPOUND AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE THEREOF The present invention belongs to the technical field of medicines, and relates to a class of aromatic heterocyclic compounds serving as an LRRK2 inhibitor. The present invention provides a class of compounds with a novel structure, which...
WO/2023/224924A1	SOLID FORMS OF A MACROCYCLIC COMPOUNDS AS CFTR MODULATORS AND THEIR PREPARATION Processes and methods of preparing Compound I are disclosed. Crystalline forms of Compound I, pharmaceutically acceptable salts, solvates, hydrates, and cocrystals thereof, pharmaceutical compositions comprising the same, methods of trea...
WO/2023/217230A1	KINESIN KIF18A INHIBITOR AND USE THEREOF The present invention provides a KIF18A inhibitor and a method for synthesizing same. The compound of the present invention can regulate KIF18A protein to influence the cell cycle and the cell proliferation process, so as to treat cancer...
WO/2023/220129A1	BENZOYPARAZINE PYRAZINES ANE THEIR USES The present disclosure features compounds of Formula I, Formula I, or pharmaceutically acceptable salts thereof, and formulations containing the same. Methods of treating BAF complex-related disorders, such as cancer, are also disclosed.
WO/2023/216871A1	EGFR INHIBITOR AND APPLICATION THEREOF A compound having a structure of formula (I), (IA), (II) or (IIA), or a pharmaceutically acceptable salt thereof, and an application of the compound or salt thereof in inhibiting an EGFR comprising a mutant EGFR, comprising treating canc...
WO/2023/218419A1	PURIFICATION PROCESS OF RIFAMPICIN FROM NITROSAMINES The present invention relates to the control of the quantity of genotoxic impurities, in particular nitrosamines, in rifampicin. In particular, the present invention relates to a process for the preparation of rifampicin substantially fr...
WO/2023/217045A1	FLUOROQUINOXALINONE DERIVATIVE FOR SELECTIVELY INHIBITING PARP1 Disclosed is a series of fluorine-substituted heterocyclic compounds, and specifically, disclosed are a compound represented by formula (XII) and a pharmaceutically acceptable salt thereof.

Matches 101 - 150 out of 12,018	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >